Irelandhorizontherapeutics.com
Horizon Therapeutics plc is an Irish-domiciled biopharmaceutical company focused on the discovery, development, and commercialization of medicines addressing critical needs in rare, autoimmune, and severe inflammatory diseases.
Founded in 2005 and headquartered in Dublin, Ireland, with operational headquarters in Lake Forest, Illinois, the company developed therapies such as Tepezza (teprotumumab) for thyroid eye disease, Krystexxa (pegloticase) for refractory gout, and treatments for conditions like cystinosis and urea cycle disorders. Its portfolio also included products for rheumatology and inflammation, including Duexis, Pennsaid, and Rayos.
Acquired by Amgen Inc. in October 2023 for approximately $27.8 billion, Horizon operates as a subsidiary, contributing to Amgen's rare disease portfolio with around 2,190 employees and 2022 revenues of $3.6 billion prior to the acquisition.
VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
Successor returns July 1 as EVP and assumes CFO duties Sept 1; outgoing CFO stays through Jan 2027 to aid transition. Successor has 30+ yrs finance leadership, ex‑CFO at Galderma, Shire, Sulzer.
Expands Puerto Rico biologics facility to boost U.S. production, deploy next‑gen technologies, support workforce development and construction jobs, and strengthen medicine supply‑chain resilience
Reese retires June 30, 2026. Effective June 1, leadership reshuffle: James Bradner named EVP R&D, AI & Data; Sean Bruich CTO; Murdo Gordon EVP Global Markets & Policy; Paul Burton remains CMO.
VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.
